KR101292026B1 - 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의동족체의 염 - Google Patents

종양 치료제로서의 이소포스포르아미드 머스타드 및 이의동족체의 염 Download PDF

Info

Publication number
KR101292026B1
KR101292026B1 KR1020077011864A KR20077011864A KR101292026B1 KR 101292026 B1 KR101292026 B1 KR 101292026B1 KR 1020077011864 A KR1020077011864 A KR 1020077011864A KR 20077011864 A KR20077011864 A KR 20077011864A KR 101292026 B1 KR101292026 B1 KR 101292026B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
ipm
cancer
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077011864A
Other languages
English (en)
Korean (ko)
Other versions
KR20070121632A (ko
Inventor
리 모간
Original Assignee
데크-테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데크-테크 인코포레이티드 filed Critical 데크-테크 인코포레이티드
Publication of KR20070121632A publication Critical patent/KR20070121632A/ko
Application granted granted Critical
Publication of KR101292026B1 publication Critical patent/KR101292026B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077011864A 2004-10-25 2005-10-25 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의동족체의 염 Expired - Fee Related KR101292026B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62208704P 2004-10-25 2004-10-25
US60/622,087 2004-10-25
US67270705P 2005-04-18 2005-04-18
US60/672,707 2005-04-18
PCT/US2005/038523 WO2006047575A2 (en) 2004-10-25 2005-10-25 Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008506A Division KR20130041384A (ko) 2004-10-25 2005-10-25 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의 동족체의 염

Publications (2)

Publication Number Publication Date
KR20070121632A KR20070121632A (ko) 2007-12-27
KR101292026B1 true KR101292026B1 (ko) 2013-08-01

Family

ID=35788704

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077011864A Expired - Fee Related KR101292026B1 (ko) 2004-10-25 2005-10-25 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의동족체의 염
KR1020137008506A Withdrawn KR20130041384A (ko) 2004-10-25 2005-10-25 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의 동족체의 염

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137008506A Withdrawn KR20130041384A (ko) 2004-10-25 2005-10-25 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의 동족체의 염

Country Status (17)

Country Link
US (4) US7678778B2 (https=)
EP (3) EP2336140B1 (https=)
JP (1) JP5336082B2 (https=)
KR (2) KR101292026B1 (https=)
CN (3) CN101087800B (https=)
AU (1) AU2005299385B2 (https=)
CA (1) CA2585125C (https=)
DK (2) DK1805192T3 (https=)
ES (2) ES2397165T3 (https=)
HK (1) HK1209752A1 (https=)
IL (3) IL182752A (https=)
NO (1) NO20072478L (https=)
NZ (2) NZ555323A (https=)
PL (1) PL1805192T3 (https=)
PT (1) PT1805192E (https=)
SI (1) SI1805192T1 (https=)
WO (1) WO2006047575A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336140B1 (en) 2004-10-25 2016-01-27 Dekk-Tec, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7964583B2 (en) 2006-02-17 2011-06-21 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
MX2009010820A (es) * 2007-04-06 2010-03-18 Ziopharm Oncology Inc Sales de mostaza isofosforamida y analogos de la misma.
NZ601139A (en) * 2008-07-31 2014-02-28 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
AU2010218109B2 (en) 2009-02-24 2015-04-09 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
CN102659841B (zh) * 2012-04-24 2015-03-25 石家庄学院 多元酚磷酰胺衍生物及其制备方法与应用
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
WO2017044453A1 (en) 2015-09-10 2017-03-16 Becton, Dickinson And Company Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
EP3684944B1 (en) 2017-09-21 2025-01-01 Becton, Dickinson and Company Hazardous contaminant collection kit and rapid testing
CN209400423U (zh) 2017-09-21 2019-09-17 贝克顿·迪金森公司 横向流测定物、测定物读取器装置和包括其的系统
CN111107939B (zh) 2017-09-21 2022-04-12 贝克顿·迪金森公司 引导有害污染物样品的收集的系统和模板及使用其的方法
USD859683S1 (en) 2017-09-21 2019-09-10 Becton, Dickinson And Company Collection device
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3856754A1 (en) * 2018-09-25 2021-08-04 The United States of America, as represented by the Secretary, Department of Health and Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
CN113383222A (zh) 2019-01-28 2021-09-10 贝克顿·迪金森公司 具有集成的拭子和测试装置的有害污染物收集装置
CN111973583A (zh) * 2020-07-29 2020-11-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 芹菜素在制备促进缺血超长随意皮瓣存活药物的作用
CN111943979B (zh) 2020-10-19 2020-12-22 南京卓康医药科技有限公司 一种异环磷酰胺中间体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
WO2000071134A1 (en) 1999-05-24 2000-11-30 Southern Research Institute Isophosphoramide mustard analogs and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU427945A1 (ru) 1972-07-24 1974-05-15 Институт элементоорганических соединений СПОСОБ ПОЛУЧЕНИЯа ПОЛИФТОРАЛКИЛЗАМЕЩЕННЫХБЕНЗИЛДИХЛОРФОСФАТОВ
JPS5159886A (https=) 1974-11-20 1976-05-25 Shionogi Seiyaku Kk
ZA851062B (en) * 1984-03-01 1985-11-27 Asta Werke Ag Chem Fab Salts of oxazaphosphorine derivatives and process for their production
ZA871260B (en) * 1986-02-22 1987-09-30 Asta Werke Ag Chem Fab Novel heterocyclic compounds having a 2-(2-(n,n-bis-(2-chloroethyl)-diamidophosphoryloxy)ethyl)radical
US4841085A (en) * 1986-06-30 1989-06-20 Board Of Regents, University Of Texas System Aldophosphamides
CA2130578A1 (en) 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
US5468499A (en) * 1993-11-15 1995-11-21 Ohio State University Liposomes containing the salt of phosphoramide mustard and related compounds
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
GB2378948B (en) 2000-04-13 2004-11-10 Hsc Res Dev Lp Novel compounds for modulating cell proliferation
DE10064312C2 (de) * 2000-12-22 2003-05-22 Degussa Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP2336140B1 (en) * 2004-10-25 2016-01-27 Dekk-Tec, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
MX2009010820A (es) 2007-04-06 2010-03-18 Ziopharm Oncology Inc Sales de mostaza isofosforamida y analogos de la misma.
NZ601139A (en) * 2008-07-31 2014-02-28 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
WO2000071134A1 (en) 1999-05-24 2000-11-30 Southern Research Institute Isophosphoramide mustard analogs and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, 1989, vol.32, pp.1768-1773 *
Journal of Medicinal Chemistry, 1995, vol.38, pp.2166-2175 *

Also Published As

Publication number Publication date
IL182752A (en) 2012-09-24
EP2336140A2 (en) 2011-06-22
WO2006047575A3 (en) 2006-08-10
US20060089333A1 (en) 2006-04-27
US7678778B2 (en) 2010-03-16
CA2585125A1 (en) 2006-05-04
AU2005299385B2 (en) 2011-06-16
IL211936A0 (en) 2011-05-31
IL182752A0 (en) 2007-07-24
JP5336082B2 (ja) 2013-11-06
HK1100945A1 (en) 2007-11-16
CN104558023A (zh) 2015-04-29
HK1209752A1 (en) 2016-04-08
DK2336140T3 (en) 2016-03-21
EP1805192A2 (en) 2007-07-11
US9346836B2 (en) 2016-05-24
CN103172662A (zh) 2013-06-26
ES2397165T3 (es) 2013-03-05
EP2336139A3 (en) 2012-01-04
US20150152125A1 (en) 2015-06-04
IL211935A0 (en) 2011-05-31
EP1805192B1 (en) 2012-10-17
EP2336140B1 (en) 2016-01-27
JP2008517949A (ja) 2008-05-29
PT1805192E (pt) 2013-01-23
EP2336140A3 (en) 2012-01-11
KR20130041384A (ko) 2013-04-24
US20080267945A1 (en) 2008-10-30
CA2585125C (en) 2014-04-22
EP2336139A2 (en) 2011-06-22
NZ589418A (en) 2012-03-30
AU2005299385A1 (en) 2006-05-04
IL211936A (en) 2012-12-31
ES2565929T3 (es) 2016-04-07
DK1805192T3 (da) 2013-02-04
PL1805192T3 (pl) 2013-03-29
US20130149296A1 (en) 2013-06-13
KR20070121632A (ko) 2007-12-27
NO20072478L (no) 2007-06-25
NZ555323A (en) 2010-12-24
CN101087800B (zh) 2015-01-07
SI1805192T1 (sl) 2013-02-28
WO2006047575A2 (en) 2006-05-04
CN101087800A (zh) 2007-12-12
US8795659B2 (en) 2014-08-05
US8232262B2 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
KR101292026B1 (ko) 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의동족체의 염
KR101505415B1 (ko) 이소포스포르아미드 머스타드의 염 및 이의 동족체
US9254298B2 (en) Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
AU2011221388B2 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7964583B2 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
HK1185884A (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
HK1100945B (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160727

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160727